IV rank extremes

Which liquid tickers had the highest and lowest 52-week implied-volatility rank on Oct 16, 2026?

The 25 highest observations appear first, followed by the 25 lowest. IV rank locates current average implied volatility between its trailing 52-week low and high; it is not an option-pricing recommendation. Data through Oct 16, 2026 close. Descriptive only, not a recommendation.

At a glance

50 tickers qualified. First five: CRWV (100.0), WBD (100.0), NU (100.0), CIFR (100.0), GME (100.0).

IV rank extremes as of Oct 16, 2026 close
#	Ticker	Close	Open interest	IV rank
1	CRWV	61.39	3,264,093	100.0
2	WBD	30.98	2,502,421	100.0
3	NU	14.56	2,068,255	100.0
4	CIFR	8.98	1,782,961	100.0
5	GME	26.81	1,653,759	100.0
6	EOSE	1.82	1,546,163	100.0
7	JBLU	2.93	1,246,059	100.0
8	RKLB	50.84	1,167,698	100.0
9	EFA	103.55	1,144,051	100.0
10	ASTS	40.66	1,104,246	100.0
11	WFC	83.87	1,093,742	100.0
12	C	124.27	1,036,714	100.0
13	BULL	6.07	1,007,854	100.0
14	RKT	10.78	1,003,165	100.0
15	POET	5.43	997,713	100.0
16	T	23.43	979,300	100.0
17	EWY	150.44	972,725	100.0
18	XOM	178.98	971,283	100.0
19	OPEN	2.12	922,215	100.0
20	RIOT	13.72	917,796	100.0
21	BA	190.21	863,959	100.0
22	LAES	1.79	836,814	100.0
23	QCOM	172.11	831,210	100.0
24	JD	27.01	806,320	100.0
25	ARM	227.80	793,099	100.0
26	VIX	20.06	15,363,220	3.8
27	MSTR	136.83	2,172,089	10.8
28	SOFI	14.55	3,825,525	16.3
29	AGNC	8.72	693,210	17.2
30	NOW	141.97	1,013,021	17.3
31	STLA	4.37	425,932	18.3
32	LAC	2.18	340,760	18.4
33	FRMI	3.16	735,157	19.4
34	RXT	2.83	122,325	19.5
35	SMCI	31.63	2,054,894	21.9
36	DRAM	46.45	2,344,615	22.6
37	UAMY	2.85	197,023	22.8
38	NFLX	70.54	4,825,393	23.2
39	UNG	10.66	325,285	23.2
40	CAG	14.47	183,508	23.4
41	TQQQ	68.21	1,501,670	24.5
42	AAPL	343.46	4,386,792	25.1
43	PCG	13.09	2,137,296	27.2
44	PSKY	9.81	308,412	27.6
45	BMNR	21.66	1,524,381	28.0
46	AES	14.95	172,488	28.3
47	ASST	24.09	267,839	29.2
48	NVAX	11.26	252,144	29.4
49	RCAT	4.72	218,185	29.5
50	NBIS	165.47	1,493,858	29.9

Screens describe what the data shows after the close. They are not trade recommendations; see the disclaimer and the methodology.